Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Operating Expenses (2021 - 2025)

Prime Medicine filings provide 5 years of Operating Expenses readings, the most recent being $49.4 million for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 6.55% to $49.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $213.0 million, a 3.67% increase, with the full-year FY2025 number at $213.0 million, up 3.67% from a year prior.
  • Operating Expenses hit $49.4 million in Q4 2025 for Prime Medicine, down from $55.2 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $68.0 million in Q4 2023 to a low of $10.4 million in Q3 2021.
  • Median Operating Expenses over the past 5 years was $49.2 million (2024), compared with a mean of $45.0 million.
  • The widest YoY moves for Operating Expenses: up 203.59% in 2022, down 35.6% in 2022.
  • Prime Medicine's Operating Expenses stood at $60.1 million in 2021, then plummeted by 35.6% to $38.7 million in 2022, then skyrocketed by 75.89% to $68.0 million in 2023, then tumbled by 31.8% to $46.4 million in 2024, then rose by 6.55% to $49.4 million in 2025.
  • The last three reported values for Operating Expenses were $49.4 million (Q4 2025), $55.2 million (Q3 2025), and $54.5 million (Q2 2025) per Business Quant data.